NURS 566 FINAL EXAM STUDY GUIDE 2019
Week 5
Prevention of osteoporosis with hormone replacement therapy (p. 433)
Hormone therapy (HT) reduces postmenopausal bone loss & thereby decreases the risk for osteoporos
...
NURS 566 FINAL EXAM STUDY GUIDE 2019
Week 5
Prevention of osteoporosis with hormone replacement therapy (p. 433)
Hormone therapy (HT) reduces postmenopausal bone loss & thereby decreases the risk for osteoporosis & related fractures. Unfortunately, when HT is stopped, bone mass rapidly decreases by approximately 12%. Hence to maintain bone health, HT must continue lifelong. As a result, the risk for harm is increased. Accordingly, alternative treatments are preferred. Effective alternatives to HT include raloxifene (Evista) & bisphosphonates like alendronate (Fosamax), calcitonin (Miacalcin), & teriparatide (Forteo). All patients should practice primary prevention of bone loss by ensuring adequate intake of calcium & vitamin D, performing regular weight-bearing exercise, & avoiding smoking & excessive alcohol use.
When and when not to use progestin for hormone replacement therapy and why (pp. 430-433)
Goals for noncontraceptive uses of progestins are to counteract endometrial hyperplasia caused by unopposed estrogen during hormone therapy; management of dysfunctional uterine bleeding, amenorrhea, & endometriosis; & support of pregnancy in women with corpus luteum deficiency. Progestins are also used in in vitro fertilization cycles & to prevent prematurity in women at high risk for preterm birth.
[Show More]
